Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 7/20 | 0.51 |
| ▸ | BACE1 | P56817 | 10/20 | 0.49 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.49 |
| ▸ | CTSD | P07339 | 1/20 | 0.49 |
| ▸ | NPY1R | P25929 | 1/20 | 0.44 |
| ▸ | NPY2R | P49146 | 1/20 | 0.44 |
| ▸ | NPY4R | P50391 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29350868 | 1.00 | FOLH1 (0.51) | FOLH1BACE1BACE2CTSDNPY1R | |
| SCHEMBL989243 | 1.00 | FOLH1 (0.51) | FOLH1BACE1BACE2CTSDNPY1R | |
| SCHEMBL31097747 | 0.97 | BACE1 (0.50) | FOLH1BACE1BACE2CTSDNPY1R | |
| SCHEMBL31097713 | 0.97 | BACE1 (0.50) | FOLH1BACE1BACE2CTSDNPY1R | |
| SCHEMBL31097722 | 0.97 | BACE1 (0.50) | FOLH1BACE1BACE2CTSDNPY1R | |
| SCHEMBL31097733 | 0.97 | BACE1 (0.50) | FOLH1BACE1BACE2CTSDNPY1R | |
| SCHEMBL31375133 | 0.96 | FOLH1 (0.55) | FOLH1BACE1BACE2CTSDNPY1R | |
| SCHEMBL30139996 | 0.96 | FOLH1 (0.55) | FOLH1BACE1BACE2CTSDNPY1R | |
| SCHEMBL29531274 | 0.96 | FOLH1 (0.55) | FOLH1BACE1BACE2CTSDNPY1R | |
| SCHEMBL30527857 | 0.96 | FOLH1 (0.55) | FOLH1BACE1BACE2CTSDNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025047921-A1 | METHOD FOR AVOIDING REJECTION REACTION | 株式会社セル―ジョン | 2025-03-06 | — | — | WO | claimed |
| US-12234262-B1 | Vaccinia virus recombinant A33R protein and kit for diagnosing antibodies against orthopoxvirus comprising the same | Republic Of Korea (Defense Acquisition Program Administration) (KR) | 2025-02-25 | — | — | US | claimed |
| US-11786552-B2 | Therapeutic compositions and applications that comprise nucleic acids and adoptively transferred immune cell | HANGZHOU CONVERO CO., LTD. (CN) | 2023-10-17 | — | — | US | claimed |
| WO-2023171835-A1 | METHOD FOR REMOVING ENDOTOXIN LPS BY USING RECOMBINANT PROTEIN COMPRISING SUSHI DOMAIN OF FACTOR C PRODUCED IN PLANT | 포항공과대학교 산학협력단 | 2023-09-14 | — | — | WO | claimed |
| CN-114196699-B | Method for increasing extracellular secretion of plant cell recombinant protein | 猎境(嘉兴)生物科技有限公司 | 2022-12-20 | — | — | CN | claimed |
| WO-2026102528-A1 | TUMOR ANTIGENS FOR LUNG CANCER AND USES THEREOF | Université de Montréal (CA) | 2026-05-21 | — | — | WO | disclosed |
| US-20260130976-A1 | NOVEL TUMOR-SPECIFIC ANTIGENS FOR MYELOID LEUKEMIA AND USES THEREOF | UNIV MONTREAL (CA) | 2026-05-14 | — | — | US | disclosed |
| US-20260102470-A1 | IMMUNOGENIC PEPTIDES SPECIFIC TO BCMA AND TACI ANTIGENS FOR TREATMENT OF CANCER | DANA FARBER CANCER INST INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12569439-B2 | Bottom-up assembly of synthetic extracellular vesicles | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-03-10 | — | — | US | disclosed |
| US-20260048105-A1 | NOVEL ANTIGENS FOR CANCER AND USES THEREOF | UNIV MONTREAL (CA) | 2026-02-19 | — | — | US | disclosed |
| EP-4695278-A1 | NOVEL TUMOR ANTIGENS FOR MELANOMA AND USES THEREOF | Université de Montréal (CA) | 2026-02-18 | — | — | EP | disclosed |
| EP-4680627-A1 | NOVEL TUMOR ANTIGENS FOR LUNG CANCER AND USES THEREOF | Université de Montréal (CA) | 2026-01-21 | — | — | EP | disclosed |
| WO-2001060393-A1 | SELECTIVE DESTRUCTION OF CELLS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS | BECHTEL BWXT IDAHO, LLC (US) | 2001-08-23 | — | — | WO | disclosed |
| EP-0571500-B1 | A HIGH SULFUR SEED PROTEIN GENE AND METHOD FOR INCREASING THE SULFUR AMINO ACID CONTENT OF PLANTS | DU PONT (US) | 2000-09-13 | — | — | EP | disclosed |
| US-5939599-A | HIGH METHIONINE; OVEREXPRESSION; GENETIC ENGINEERING; NUTRITION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-08-17 | — | — | US | disclosed |
| US-5559223-A | Synthetic storage proteins with defined structure containing programmable levels of essential amino acids for improvement of the nutritional value of plants | E. I. DUPONT DE NEMOURS AND COMPANY (US) | 1996-09-24 | — | — | US | disclosed |
| EP-0598806-A1 | SYNTHETIC STORAGE PROTEINS WITH DEFINED STRUCTURE CONTAINING PROGRAMMABLE LEVELS OF ESSENTIAL AMINO ACIDS FOR IMPROVEMENT OF THE NUTRITIONAL VALUE OF PLANTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-06-01 | — | — | EP | disclosed |
| EP-0571500-A1 | A HIGH SULFUR SEED PROTEIN GENE AND METHOD FOR INCREASING THE SULFUR AMINO ACID CONTENT OF PLANTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-12-01 | — | — | EP | disclosed |
| WO-1993003160-A1 | SYNTHETIC STORAGE PROTEINS WITH DEFINED STRUCTURE CONTAINING PROGRAMMABLE LEVELS OF ESSENTIAL AMINO ACIDS FOR IMPROVEMENT OF THE NUTRITIONAL VALUE OF PLANTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-02-18 | — | — | WO | disclosed |
| WO-1992014822-A1 | A HIGH SULFUR SEED PROTEIN GENE AND METHOD FOR INCREASING THE SULFUR AMINO ACID CONTENT OF PLANTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260130976-A1 | NOVEL TUMOR-SPECIFIC ANTIGENS FOR MYELOID LEUKEMIA AND USES THEREOF | MICA, TAP1, CD74 | FOLH1 2992/4885BACE1 4015/4885BACE2 4518/4885 |
| US-20260102470-A1 | IMMUNOGENIC PEPTIDES SPECIFIC TO BCMA AND TACI ANTIGENS FOR TREATMENT OF CANCER | MICA, TAP1, CD74 | FOLH1 758/4885BACE1 1682/4885BACE2 1994/4885 |
| US-20260048105-A1 | NOVEL ANTIGENS FOR CANCER AND USES THEREOF | MICA, HLA-DRB1, CD74 | FOLH1 2269/4885BACE1 2223/4885BACE2 3274/4885 |
| US-12569439-B2 | Bottom-up assembly of synthetic extracellular vesicles | EXOSC10, PLTP, EXOSC9 | FOLH1 1263/4885BACE1 1449/4885BACE2 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.